final.tsd.in {Power2Stage} | R Documentation |
Analysis after second stage of 2-stage 2x2 crossover design based on the Inverse Normal method
Description
Following the design scheme according to power.tsd.in
the function
performs the analysis after the second stage has been performed.
Usage
final.tsd.in(alpha, weight, max.comb.test = TRUE, GMR1, CV1, n1, df1 = NULL,
SEM1 = NULL, GMR2, CV2, n2, df2 = NULL, SEM2 = NULL,
theta1, theta2)
Arguments
alpha |
If one element is given, the overall one-sided significance level (not the
adjusted level for stage 2). If two
elements are given, the adjusted one-sided alpha levels for
stage 1 and
stage 2, respectively. |
weight |
Pre-defined weight(s) of stage 1.
Note that using the notation from Maurer et al weight corresponds to
information fraction, other literature may refer to sqrt(weight) as
being the weight. |
max.comb.test |
Logical; if |
GMR1 |
Observed ratio of geometric means (T/R) of stage 1 data (use e.g., 0.95 for 95%). |
CV1 |
Observed coefficient of variation of the intra-subject variability of stage 1 (use e.g., 0.3 for 30%). |
n1 |
Sample size of stage 1. |
df1 |
Optional; Error degrees of freedom of
stage 1 that can be specified in
addition to |
SEM1 |
Optional; Standard error of the difference of means of
stage 1 that can be specified in
addition to |
GMR2 |
Observed ratio of geometric means (T/R) of (only) stage 2 data (use e.g., 0.95 for 95%). |
CV2 |
Observed coefficient of variation of the intra-subject variability of (only) stage 2 (use e.g., 0.3 for 30%). |
n2 |
Sample size of stage 2. |
df2 |
Optional; Error degrees of freedom of (only)
stage 2 that can be specified in
addition to |
SEM2 |
Optional; Standard error of the difference of means of (only)
stage 2 that can be specified in
addition to |
theta1 |
Lower bioequivalence limit. Defaults to 0.8. |
theta2 |
Upper bioequivalence limit. Defaults to 1.25. |
Details
The observed values GMR1
, CV1
, n1
must be obtained
using data from stage 1 only, and GMR2
, CV2
, n2
must
be obtained using data from stage 2 only. This may be done via the usual
ANOVA approach.
The optional arguments df1
, SEM1
, df2
and SEM2
require a somewhat advanced knowledge (provided in the raw output from for
example the software SAS, or may be obtained via emmeans::emmeans
).
However, it has the advantage that if there were missing data the exact
degrees of freedom and standard error of the difference can be used,
the former possibly being non-integer valued (e.g. if the
Kenward-Roger method was used).
Value
Returns an object of class "evaltsd"
with all the input arguments and results
as components. As part of the input arguments a component cval
is also
presented, containing the critical values for stage 1 and 2 according to the
input based on alpha
, weight
and max.comb.test
.
The class "evaltsd"
has an S3 print method.
The results are in the components:
z1 |
Combination test statistic for first null hypothesis (standard
combination test statistic in case of |
z2 |
Combination test statistic for second null hypothesis (standard
combination test statistic in case of |
RCI |
Repeated confidence interval for stage 2. |
MEUE |
Median unbiased point estimate as estimate for the final adjusted geometric mean ratio after stage 2. |
stop_BE |
Logical, indicating whether BE can be concluded after stage 2 or not. |
Author(s)
B. Lang
References
König F, Wolfsegger M, Jaki T, Schütz H, Wassmer G.
Adaptive two-stage bioequivalence trials with early stopping and sample size re-estimation.
Vienna: 2014; 35th Annual Conference of the International Society for Clinical Biostatistics. Poster P1.2.88
doi: 10.13140/RG.2.1.5190.0967.
Patterson SD, Jones B. Bioequivalence and Statistics in Clinical Pharmacology.
Boca Raton: CRC Press; 2nd edition 2017.
Maurer W, Jones B, Chen Y. Controlling the type 1 error rate in two-stage
sequential designs when testing for average bioequivalence.
Stat Med. 2018; 37(10): 1587–1607. doi: 10.1002/sim.7614.
Wassmer G, Brannath W. Group Sequential and Confirmatory Adaptive Designs
in Clinical Trials.
Springer 2016. doi: 10.1007/978-3-319-32562-0.
See Also
Examples
# Example from Maurer et al.
final.tsd.in(GMR1 = exp(0.0424), CV1 = 0.3682, n1 = 20,
GMR2 = exp(-0.0134), CV2 = 0.3644, n2 = 36)
# Example 2 from Potvin et al.
final.tsd.in(GMR1 = 1.0876, CV1 = 0.18213, n1 = 12,
GMR2 = 0.9141, CV2 = 0.25618, n2 = 8)